Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back PainFrederick, MD - (NewMediaWire) - March 8, 2019 - BioElectronics Corporation (OTC PINK: BIEL) http://www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The objectives of this additional back pain study are to support Mundipharma’s Australia and New Zealand sales and marketing, provide local economic data for product reimbursement, and to document ActiPatch’s effectiveness on central sensitization pain.Chronic low back pain is very challenging to treat given its association with “central sensitization”, as sufferers experience exaggerated pain perception [2] and are often resistant to standard treatments. Sree Koneru, Ph.D., VP of Product Development at BioElectronics, said, “There is already real-world and clinical evidence that ActiPatch is effective in reducing back pain [3]. More than 30 million Americans are affected by chronic low back pain, collectively spending more than $90 billion annually in treatment costs [1]”.The study will involve 142 subjects who have been suffering with low back pain for more than 3 months at the time of enrollment into the study, which is scheduled to take place over a 30-day period and involve two visits. During the first visit, baseline data about the subject, including pain intensity, functionality and sleep quality will be collected. They will then receive, randomly, either an active or sham ActiPatch device along with instructions on how to use it for the next 30-days. During the final follow up visit, additional data will be collected to evaluate improvements in pain and other outcome measures. Full details about the study can be found at the NIH’s clinical trials listing page (https://clinicaltrials.gov/ct2/show/NCT03828864), as well as the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619000136101)The study is being conducted by the Pain Management Center of the prestigious Royal Prince Alfred Hospital in Sydney, Australia. The principal investigator (PI) leading the study is Graeme Campbell, a physiotherapist, supported by his team of physicians and clinical researchers.Dr. Sree Koneru, Ph.D. is presenting at the Australian Pharmacy Professional Conference & Trade Exhibition in Melbourne, Australia from March 7th, 2019 to March 10th, 2019, “Electroceuticals – effective non-pharmacological treatments as part of multimodal pain management.”References[1] M. A. Davis, "Where the United States Spends Its Spine Dollars: Expenditures on different ambulatory services for the management of back and neck conditions," Spine, pp. 1693-1701, 2013.[2] S. et.al., "Central sensitization in chronic low back pain: A narrative review.," J. Back Muscloskeletal Rehabil., pp. 625-633, 2016.[3] R. Staelin, S. Koneru and I. Rawe, "Chronic Back Pain Therapy Using the ActiPatch: A Registry of Pain Relief, Medical Use and its Side Effects," Pain Management , vol. 7, no. 2, pp. 99-111, 2017.About BioElectronics CorporationBioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.Contact: Paul Knopick pknopick@eandecommunications.com 940.262.3584
Houston, TX - (NewMediaWire) - March 08, 2019 - D3esports, a division of StemGen, Inc. (OTC: SGNI), has launched its first Virtual to Real Motorsports Experience Center with the Visit Houston Marketplace in Houston, Texas. The custom-built SIMxlr8 game pod is a state-of-the-art three-screen simulator, complete with interactive steering wheel and pedals, as well as a real racing seat. It offers the user the opportunity to feel the rush of high-speed racing both in the virtual realm and on the race track. The D3esports experience on the VisitHouston.com website marketplace is currently in the Top 5 marketplace destination for visitors, rated higher than the NASA Space Center Experience. The D3esports Virtual to Real Racing Experience offers 45 minutes of virtual laps on a state-of-the-art simulator, followed by 15 minutes of real laps on the track in a professional race car. The location is at the MSR Houston circuit in the southern suburbs of Houston and offered to anyone 15 years or older for a fee of $575 USD. (See https://experience.visithouston.com/checkout/3/visit-houston/8/houston-marketplace/product/14908/virtual-to-real-racing-experience) The SIMxlr8 game pod is evolutionary, patent-pending and fully upgradeable for a true driving experience and built by actual racers who know how to win on the track and online. After the Virtual to Real experience there is an opportunity to rent and get behind the wheel of a prototype race car and learn about aerodynamic with more to come on this virtual to real education platform. “Our engineers and drivers believe we have the best simulator products on the market for personal, educational, and commercial use,” said Simon Dawson, CEO/President of StemGen and D3esports. “The launch of the VisitHouston.com Virtual to Real Motorsports Experience Center has been incredibly successful in a short amount of time. The SIMxlr8 products line has been used in successful commercial and hospitality applications. When you become a retail or distributor partner, you have an instant new profit center. We’re excited about the interest in these Experience Centers and have big plans to open many more in the coming months and have global plans with this program.” As D3esports grows the virtual to real gaming platform in the motorsports industry, additional D3esports Experience Centers are planned to be launched in the coming months, including internationally. For more information on either the Experience Center or purchase of the D3esports game pods, contact info@d3esports.com. D3esports was founded in May 2018 and launched in July 2018 at Dave and Buster’s Houston flagship location. Through their D3 division, the company has extensive experience in real motorsports for over 40 years.ABOUT STEMGEN, INC.StemGen, Inc. (https://stemgencorp.com/), a Delaware corporation based in Angleton, Texas, is a virtual to real gaming platform in the motorsports industry. NOTICE REGARDING FORWARD LOOKING STATEMENTSSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.CONTACT: Barbara J. Burns, BurnsGroup PR barbara@burnsgrouppr.com or +1 770-329-7134
Industry Veteran John P. Sentman to Lead Strategic Sales and PartneringMIRAMAR, FL - (NewMediaWire) - March 08, 2019 - Olaregen Therapeutix, a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of John P. Sentman as Vice President of Business Strategy. In his position, Mr. Sentman will lead and coordinate the activities and operations of the business strategy department responsible for executing all aspects of the organization’s overall business strategy, sales and market planning, and financial forecasts.Mr. Sentman has over 30 years of experience in commercial, marketing, and strategic planning roles within the medical device industry, primarily in the wound care field. He joins Olaregen from Integra Life Sciences where he was Senior Director of Global Marketing for Regenerative Technologies, overseeing brand marketing of the company’s soft tissue repair portfolio. Prior to Integra, Mr. Sentman held various sales, management, and marketing roles, both domestically and internationally over a 20-year career with ConvaTec, a leading manufacturer of wound care products. Mr. Sentman received his bachelor’s degree in finance from American University’s School of Business.“We are extremely pleased to have John leading business strategy, market development and the commercial launch of Excellagen,” said Anthony Dolisi, CEO of Olaregen and Chief Commercial Officer of Generex. “His extensive wound care experience and market knowledge will be instrumental to the company’s commercial success.”Mr. Sentman commented on his new position, “I welcome the opportunity to launch and build the Excellagen brand as the leading Cellular Tissue Product in treating hard-to-heal wounds, and I look forward to working closely with the Olaregen team.”About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.About Olaregen TherapeuticsOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, ...
NutraHempCBD celebrates St. Patrick’s Day with 40% off a 600mg Full Spectrum Tincture and a Pet Wellness Tincture combo!Coconut Creek, FL - (NewMediaWire) - March 8, 2019 - NutraHempCBD, a line of hemp-derived cannabidiol (CBD) products from the life sciences company, Nutralife Biosciences, Inc. (Nutralife or “the Company”) is celebrating St. Patrick’s Day by offering 40% off when you buy a 600mg Full Spectrum Tincture and a Pet Wellness Tincture! The promo price will be $80, that’s reduced from the original $135 sticker price.NutraHempCBD full spectrum cannabidiol formula has 600 mg of hemp-derived CBD in every bottle and has been hailed by consumers as a convenient way to reap the benefits of full-spectrum cannabidiol. This NutraHempCBD formula comes in an easy-to-dose spray instead of an oily dropper and customers can expect delivery of 14 mg of full-spectrum hemp-derived CBD per six-spray serving. The hemp utilized is grown on a USDA Certified Organic farm and the formula is flavored with stevia leaf extract for a superior taste.The NutraPet Drops are for your furry friends! Our pet CBD products are designed to provide anti-inflammatory and overall wellness factors. Our pet-friendly formula comes in convenient CBD drops that can be added directly to your pet’s favorite food or treat. The drops deliver 8.33 mg hemp-derived full spectrum CBD per serving and just like our human spray the CBD is from hemp grown on an organic farm.NutraLife Biosciences, Inc., formerly known as NutraFuels, Inc., (“NutraLife” or the “Company”) also recently announced a name change to NutraLife BioSciences, Inc. and new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations.The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online atwww.nutrahempcbd.com and by following the company on Instagram.* These statements have not been evaluated by the Food and Drug Administration.* This product is not intended to diagnose, treat, cure or prevent any disease.Forward-Looking StatementsThis communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a ...
New York, NY - (NewMediaWire) - March 8, 2019 - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has placed an order with its manufacturer for the production of additional Tauri-Gum™ inventory at this time. The Company believes that this decision is prudent, due to stronger than expected initial indications of demand from a broad array of prospective distributors and customers. On March 7, 2019, the Company placed an order with its manufacturer for an additional 8,700 individual packs; delivery to the Company (for this 2ndinventory tranche) is expected during mid-April 2019. The Company continues to realize significant progress on a number of different initiatives and is excited for its upcoming commercial launch (later this month) of its CBD infused chewing gum product line, branded as Tauri-Gum™. In other news, the Company continues to be in productive discussions with Amazon and is hopeful that Tauri-Gum™ will be approved for listing, in the near term.ABOUT: TAURIGA SCIENCES, INC.Tauriga Sciences, Inc. (TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-GumTM. See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com. In addition, the Company is currently constructing an E-Commerce site for the sale of its CBD Infused Chewing Gum. This site is being constructed under the following URL address: www.taurigum.comForward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not ...
Scottsdale, AZ - (NewMediaWire) - March 08, 2019 - CBD Life Sciences Inc. (OTC: CBDL) is pleased to announce that its wholly owned subsidiary, LBC Bioscience, Inc., has now finalized the formulization for and is launching an organic - GMO free - CBD based anti-aging product line. The product line includes: anti-aging day serum, CBD based eye gel, nourishing face serum with retinol, blemish balancing serum, CBD vitamin C face serum, and CBD based face cream. The Global Anti-Aging Market was worth $42.51 Billion in 2018 and estimated to $55.03 Billion by 2023. LBC Bioscience, Inc. is positioning itself to be a leader in CBD based anti-aging and is already in talks with a number of companies to ‘white label’ the product line. In addition, LBC Bioscience, Inc. is working with Dr. Farhan Taghizadeh of Arizona Facial Plastics P.C. to develop a case study showing the effectiveness of the product line. Arizona Facial Plastics is a leading cosmetic surgery based in Phoenix, Arizona. About CBD Life Sciences Inc.CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘OCSYD’. The Company’s main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.About LBC Bioscience Inc. LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions, supplements, edibles, and a full line of pet products. In addition, LBC is in the process of developing an anti-aging skin product line. LBC’s products can be viewed and purchased on the company’s website at www.lbcbioscienceinc.com.Contact InformationInvestor RelationsTen Associates LLC11529 N. 120th St.Scottsdale, Arizona85259 USATelephone: 480-326-8577Thomas E. NelsonEmail: tenassociates33@gmail.comForward-Looking StatementsExcept for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.Safe Harbor StatementThis release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
New York NY - (NewMediaWire) - March 08, 2019 - NexTech AR Solutions (the “Company” or “NexTech”) (OTC: NEXCF) (CSE: NTAR) (FSE: N29), a technology and emerging commercial growth company focused on bringing augmented reality (“AR”) to the masses through its web-enabled AR platform for eCommerce, announced today that further to the Company’s press release dated February 5, 2019, the previously announced warrant call ended on March 7, 2019 and the $0.50 warrants dated March 29, 2018 are no longer exercisable.● 2,929,200 warrants were exercised during the 30 day acceleration period for proceeds totaling $1,464,600.● The Company has 54,049,372 common shares issued and outstanding. ● 5,502,100 warrants expired on March 7, 2019.● Cash position is now $3,500,000The Company is actively looking for additional acquisitions and continuing to develop its new business pipeline, targeting high-growth verticals such as eCommerce, Education & Training, and Live Streaming & Telepresence, with an initial focus on the global retail eCommerce market, projected to reach $4.8 trillion in 2021, according to Statistica. Recent research has shown that 40% of online shoppers would be willing to pay more for a product if they could experience it through AR, while 71% of shoppers indicated they would shop at a brand more often if it offered AR experiences.About NexTech AR Solutions Corp.NexTech is bringing a next generation web enabled augmented reality (AR) platform with Artificial Intelligence (AI) and analytics to the Cannabis industry, eCommerce, education, training, healthcare and video conferencing. Having integrated with Shopify, Magento and Wordpress its technology offers eCommerce sites a universal 3D shopping solution. With just a few lines of embed code, the company’s patent-pending platform offers the most technologically advanced 3D-AR, AI technology anywhere. Online retailers can subscribe to NexTech’s state of the art, 3D-AR/AI solution for $79/mo. The company has created the AR industry’s first end-to-end affordable, intelligent, frictionless, scalable platform.For further information, please contact:Evan GappelbergChief Executive Officerinfo@nextechar.com Media contact:Erin HaddenFischTank Marketing and PRehadden@fischtankpr.comThe CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
Statement Highlights: Smoking tobacco in hookahs results in inhaling significant levels of toxic chemicals, such as carbon monoxide, and particulates from tobacco that can harm blood vessels and the heart. Globally, hookah smoking is more common among youth and young adults, encouraged by flavored tobacco marketing, social media promotion and misperceptions regarding its addictive potential and health effects. Embargoed until 4 a.m. CT / 5 a.m. ET Friday, March 8, 2019 (NewMediaWire) - March 08, 2019 - DALLAS - Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels exceeding cigarette smoke, that may harm the heart and blood vessels, according to a new scientific statement published in the American Heart Association’s journal Circulation. Waterpipes go by many names - hookah, narghile, argileh, shisha and goza – and usually consist of a head or bowl that holds tobacco, a body, water base and hose that ends with a mouthpiece. Burning charcoal is placed on top of the tobacco-filled bowl. Hookah tobacco is usually a combination of dried fruit, flavored tobacco and substances to keep the tobacco moist. During a hookah smoking session that typically last for 30 or more minutes, users inhale many liters of smoke filled with large quantities of particulate matter at higher concentrations than cigarettes. Although direct comparisons between hookahs and cigarettes have some limitations, a single session of hookah use typically results in greater exposure to carbon monoxide than a single cigarette. Even short-term exposure to carbon monoxide in hookahs is toxic and can interfere with exercise capacity, according to the statement authors. In addition to carbon monoxide, hookah smoke contains other potentially harmful chemicals that can affect the cardiovascular system, including nicotine, air pollutants, particulate matter, volatile organic chemicals, polycyclic aromatic hydrocarbons, acrolein, lead, cadmium and arsenic. Most of these toxins are higher in hookah than cigarette smoke. “Hookah smoke contains harmful substances and the American Heart Association strongly recommends avoiding the use of tobacco in any form,” said Aruni Bhatnagar, Ph.D., chair of the writing group for the statement and professor of medicine and director of the University of Louisville Diabetes and Obesity Center in Kentucky. There is growing evidence that hookah tobacco smoking acutely impacts heart rate and blood pressure. Chronic use is associated with increased coronary artery disease risk. “Many young people mistakenly believe that smoking tobacco from a hookah is less harmful than cigarette smoking because the tobacco if filtered through water, but there is no scientific evidence that supports that claim. However, there is evidence to suggest that hookah smoking is addictive and can lead to the use of other tobacco products such as cigarettes,” said Bhatnagar. The spread of hookah smoking, especially among young people, is promoted by several factors, including sweetened and flavored hookah tobacco, social media that promotes this method of tobacco use and misperceptions regarding its addictive potential and adverse health effects. Unlike cigarette tobacco, hookah tobacco, often colorfully packaged, can be sold in candy and fruit flavors, which appeal to younger audiences. The flavors and sweeteners added to the tobacco mask the harshness of smoke, making it easier to start and continue smoking hookahs. In addition, because many people smoke hookah in lounges and cafes it is perceived to be a social activity and less habit-forming. More importantly, most of the tobacco marketed to hookah users does not carry a health warning, leading to the misperception that it is not harmful. In the United States, recent surveys have estimated hookah usage that range from 4. 8 percent among high school students to 13.6 percent of young adults (18-24 years old). People 18-24 years of age also accounted for 55 percent of hookah smokers nationwide. In addition, those who use a hookah are more likely ...
New York, March 07, 2019 (NewMediaWire) -- Weyland Tech Inc. (WEYL) (“Weyland” or the “Company”) announces updates coinciding with an investor conference call held on March 7, 2019 at 12 noon EST.In addition to updates on the Company’s core PaaS business and its eWallet, AtozPay, the following major initiatives and objectives are underway and in various stages:Expression of Interest for acquisition of the AtozPay business by a large regional tech companyUpdate on outstanding litigation in Singapore and US Federal court in NevadaPotential for merger and expansion into new emerging marketQualification for NASDAQ and re-engagement of applicationPotential for acquisition of the AtozPay business by a large regional tech companyAs announced on September 6, 2018, there has been an increase in private fundings, IPOs and merger and acquisition activity leading to the emergence of large ‘unicorn’ companies competing for marketshare in SE Asia. In February, the Company received an expression of interest in the acquisition of its eWallet business from a regional leader in ride-sharing and delivery. Comparable valuation metrics make this a source of encouragement as we follow through on our mandate at Weyland to build, grow, and sell the businesses that we launch in emerging markets.Our team in Indonesia continues to build the platform making it attractive to potential acquirers and the landscape continues to improve for a sale.Potential for merger and expansion into new emerging marketManagement has identified and begun an initiative for entry into our second emerging market in SE Asia. During this process the possibility of a merger with a larger group possessing country licensing and infrastructure needed for rapid expansion has been raised. There have been numerous meetings, calls and terms proposed and should there be a firm agreement, we will pursue it with our Board of Directors and subsequently inform shareholders.Update on outstanding litigation in Singapore and US Federal court in NevadaRegarding the current litigation in Singapore and in the US Federal Court in Nevada, over the past two months there has been substantial progress and we remain optimistic that a settlement favorable to shareholders is imminent. Qualification for NASDAQ and re-engagement of applicationThe management team has moved forward re-opening our NASDAQ application and, based upon meetings and discussions with NASDAQ, the Company currently qualifies under most of the criteria for a NASDAQ listing. As we progress, we will inform shareholders.About Weyland Tech Inc.Weyland Tech is a global provider of mobile business applications. The Company operates a Platform-as-a-Service (“PaaS”) software used on mobile ‘smartphones’. The PaaS platform offers a mobile presence to Small-to-Medium-Sized- Businesses (“SMB’s”) in emerging markets, with partnerships on 3 continents and growing. The PaaS platform, offered in 14 languages with over 70 integrated modules, enables SMB’s to create native mobile applications (“apps”) for Apple’s iOS and Google Android without technical knowledge or background, empowering SMB’s to increase sales, reach more customers and promote their products and services in an easy, affordable and efficient manner.About WIP/AtoZPayWeyland Indonesia Perkasa (“WIP”) / AtoZPay is an Indonesian Company that is held by Weyland Tech via both equity and contractual structures which comply with Indonesia’s foreign commercial ownership regulations. AtoZPay, an eWallet solution, is quickly becoming the adopted standard in Indonesia, the world’s 4th most populous nation, with a majority of consumers without bank accounts. A partnership with Finnet, Indonesia’s state-controlled company tasked with building and supporting banking and finance infrastructure nationwide, and a recently achieved banking license, creates the most robust solution for the “unbanked” in Indonesia. Weyland Tech owns 100% the eWallet software platform which powers AtozPay. In a liquidity event or outright exit via an acquisition, Weyland and its sub-holding (WAI) are entitled ...
Study Highlights: Women who have lost at least 10 pounds, only to regain the weight within a year, are more likely to have a poor score on the American Heart Association’s - Life’s Simple 7, a measure of how well people control important heart disease risk factors. The more episodes of yo-yo dieting women report, the worse they score on Life’s Simple 7. In addition to achieving a healthy weight, maintaining a consistent body weight may be important for lowering heart disease risk. Embargoed until 3 p.m. CT/ 4 p.m. ET, Thursday, March 7, 2019 (NewMediaWire) - March 07, 2019 - HOUSTON - Yo-yo dieting may make it harder for women to control a variety of heart disease risk factors, according to preliminary research presented at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2019, a premier global exchange of the latest advances in population-based cardiovascular science for researchers and clinicians. “Achieving a healthy weight is generally recommended as heart healthy but maintaining weight loss is difficult and fluctuations in weight may make it harder to achieve ideal cardiovascular health,” said Brooke Aggarwal, Ed.D., M.S., senior author of the study and assistant professor of medical sciences at Columbia University Vagelos College of Physicians and Surgeons in New York. Investigators studied 485 women (average age 37 years, 61 percent racial/ethnic minorities, average body mass index 26, in the overweight range) participating in the American Heart Association’s Go Red for Women Strategically Focused Research Network at Columbia University in New York City. Women reported how many times (other than during pregnancies) they had lost at least 10 pounds, only to regain the weight within a year. They were assessed on American Heart Association’s - Life’s Simple 7, a measure of how well people control important heart disease risk factors (including body mass index, cholesterol, blood pressure, blood sugar, smoking, physical activity and diet). Most of the women (73 percent) reported at least one episode of yo-yo weight loss, with a range of zero to 20 episodes. Researchers found that women with one or more episodes of yo-yo weight loss were: 82 percent less likely to have an optimal body mass index (between 18.5 and 25, neither underweight or overweight for their height); and 51 percent less likely to be rated as moderate, and 65 percent less likely to be rated as optimal overall on Life’s Simple 7. The more episodes of weight cycling women reported, the poorer they scored on Life’s Simple 7, according to the researchers. The detrimental impact of weight-cycling on the overall Life’s Simple 7 score was most striking in women who had never been pregnant. “The women without a pregnancy history were likely younger and might be those who started weight-cycling at an earlier age. We need to identify critical periods for the effect of weight fluctuation on heart disease risk over the life course to find out whether it is worse when women start on a dieting roller-coaster at an early age,” said Aggarwal. The study is limited in not differentiating unintentional from intentional weight loss, and in being based on self-reported data and measures taken at a single time. Aggarwal stressed that the team cannot currently tease apart whether yo-yo dieting has adverse effects on Life’s Simple 7 factors or rather that those who don’t adhere to guidance on Life’s Simple 7 have a harder time maintaining low weight and end up yo-yo dieting more frequently. The study’s results in women may not be generalizable to men. “We hope to extend the study five to ten years to confirm these results and look at long-term effects,” Aggarwal said. “However, there has been prior research that showed similar results in men, with those who weight-cycled having twice the risk of cardiovascular death in middle age.” Co-authors are: Stephanie S. Byun, M.S.; Natalie A. Bello, M.D., M.P.H.; Ming Liao, M.S.; and Nour Makarem, Ph.D., M.S. Author disclosures are on the abstract. The American ...
